CG Oncology to Present Late-Breaking Abstract and Key Research on Cretostimogene Grenadenorepvec at 40th Annual EAU Congress

CG Oncology will present key findings on cretostimogene grenadenorepvec at the 40th Annual EAU Congress in Madrid.

Quiver AI Summary

CG Oncology, Inc. announced that it will present a late-breaking abstract and three posters at the 40th Annual European Association of Urology (EAU) Congress in Madrid from March 21-24, 2025. The presentations will focus on cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy being evaluated in late-stage trials for high-risk non-muscle invasive bladder cancer (NMIBC) that is unresponsive to BCG therapy. Key presentations include updated clinical results from the BOND-003 Cohort C study, analyses correlating genomic disease burden with treatment outcomes, and ongoing trials of cretostimogene in various settings. CG Oncology aims to develop innovative therapies for bladder cancer, enhancing patient quality of life, while the safety and efficacy of cretostimogene have yet to be established by health authorities.

Potential Positives

• CG Oncology will present significant clinical research findings at the prestigious 40th Annual European Association of Urology Congress, enhancing its visibility within the urology field.
• The late-breaking abstract on the BOND-003 trial and three posters on cretostimogene grenadenorepvec suggest promising developments in treatment options for patients with bladder cancer.
• The involvement of leading medical professionals from renowned institutions, such as the University of Pennsylvania and MD Anderson Cancer Center, underscores the credibility and potential impact of CG Oncology's research.
• The focus on innovative immunotherapies positions CG Oncology as a key player in advancing treatment for high-risk non-muscle invasive bladder cancer, which could lead to improved patient outcomes.

Potential Negatives

• The press release emphasizes that the safety and efficacy of cretostimogene grenadenorepvec have not been established by the FDA or any other health authority, which may raise concerns about the product's viability and regulatory status.
• Focusing on presentation at an upcoming congress rather than providing substantive data on clinical trial results may indicate that the company lacks significant new findings to report.
• As this product is still investigational, the lack of definitive positive outcomes could impact investor confidence and market perception of CG Oncology's future prospects.

FAQ

What is the focus of CG Oncology?

CG Oncology focuses on developing and commercializing therapies for bladder cancer, particularly bladder-sparing options.

When will CG Oncology present at the EAU Congress?

CG Oncology will present from March 21-24, 2025, at the 40th Annual EAU Congress in Madrid, Spain.

What is cretostimogene grenadenorepvec?

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy for high-risk non-muscle invasive bladder cancer.

What are the key presentations at the congress?

Key presentations include updated results from the BOND-003 study and findings from the PIVOT-006 trial.

Who is presenting the late-breaking abstract?

The late-breaking abstract will be presented by Dr. Trinity J. Bivalacqua at the EAU Congress.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$CGON Insider Trading Activity

$CGON insiders have traded $CGON stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $CGON stock by insiders over the last 6 months:

• HONG FANG SONG sold 700,000 shares for an estimated $19,600,000
• LEONARD E POST has made 0 purchases and 4 sales selling 3,000 shares for an estimated $93,041.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$CGON Hedge Fund Activity

We have seen 88 institutional investors add shares of $CGON stock to their portfolio, and 57 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• FMR LLC added 2,287,987 shares (+1571.4%) to their portfolio in Q4 2024, for an estimated $65,619,467
• MARSHALL WACE, LLP added 1,450,372 shares (+18836.0%) to their portfolio in Q4 2024, for an estimated $41,596,668
• WELLINGTON MANAGEMENT GROUP LLP added 1,400,251 shares (+274.4%) to their portfolio in Q4 2024, for an estimated $40,159,198
• RA CAPITAL MANAGEMENT, L.P. removed 1,397,433 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $40,078,378
• BVF INC/IL removed 994,596 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $28,525,013
• UBS GROUP AG added 927,357 shares (+1071.7%) to their portfolio in Q4 2024, for an estimated $26,596,598
• DECHENG CAPITAL LLC added 892,859 shares (+16.3%) to their portfolio in Q4 2024, for an estimated $25,607,196

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that a late-breaking abstract on BOND-003 Cohort C, as well as three posters highlighting cretostimogene grenadenorepvec, will be presented at the 40

^th

Annual European Association of Urology (EAU) Congress taking place in Madrid, Spain, from March 21-24, 2025. The Annual EAU Congress is Europe’s biggest urological event, where thousands of healthcare professionals from around the world gather to present research and learn about the latest innovations in patient care.

CG Oncology will have a series of key presentations and updates on cretostimogene grenadenorepvec including:

Updated clinical & translational results: BOND-003 Cohort C- A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ

Late Breaking Abstract Number:

LB12



Session:

Abstract Session 45 - NMIBC: Innovations and outcomes 1



Presenter:

Trinity J. Bivalacqua, M.D., Professor of Urology and Oncology at the Perelman Center for Advanced Medicine, University of Pennsylvania, Division of Urology and the Director of Urology Oncology and GU Service Line in the Cancer Center.


Presentation Date & Time: March 24, 2025, 10:45 - 12:15 CET


Location: Pink Area N101, Ifema, Madrid

Translational correlates using urinary genomic disease burden to assess cretostimogene grenadenorepvec: Analysis from the BOND-003 and CORE-001 trials





Abstract Number:

A0793



Session:

Abstract Session 45 - NMIBC: Innovations and outcomes 1



Presenter:

Sharada Mokkapati, Ph.D., Basic Science Faculty, Department of Urology, University of Texas MD Anderson Cancer Center


Presentation Date & Time: March 24, 2025, 10:45 - 12:15 CET


Location: Pink Area N101, Ifema, Madrid

BOND-003 cohort P - a multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high-risk, papillary only, BCG-unresponsive non-muscle invasive bladder cancer





Abstract Number:

A0083



Session:

Abstract Session 05 - On the horizon: Ongoing trials in urology



Presenter:

Siamak Daneshmand, M.D., Director of Urologic Oncology at USC/Norris Comprehensive Cancer Center



Presentation Date & Time:

March 21, 2025, 15:15 - 16:45 CET



Location:

Green Area Retiro, Ifema, Madrid

PIVOT-006 - a phase 3, randomized study of adjuvant intravesical cretostimogene grenadenorepvec versus surveillance for the treatment of intermediate-risk non-muscle invasive bladder cancer





Abstract Number:

A0082



Session:

Abstract Session 05 - On the horizon: Ongoing trials in urology



Presenter:

Siamak Daneshmand, M.D., Director of Urologic Oncology at USC/Norris Comprehensive Cancer Center



Presentation Date & Time:

March 21, 2025, 15:15 - 16:45 CET



Location:

Green Area Retiro, Ifema, Madrid

About Cretostimogene Grenadenorepvec

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy being evaluated in BOND-003, a Phase 3 clinical trial for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy. Cretostimogene is also being evaluated in a Phase 3 monotherapy clinical trial (PIVOT-006) in patients with intermediate-risk NMIBC. In addition, cretostimogene is being evaluated in an investigator-sponsored clinical trial in combination with nivolumab for the treatment of muscle invasive bladder cancer.

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy candidate, and its safety and efficacy have not been established by the FDA or any other health authority.

About CG Oncology



CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit:

www.cgoncology.com

.

Contacts:



Media


Sarah Connors


Vice President, Communications and Patient Advocacy, CG Oncology


(508) 654-2277



sarah.connors@cgoncology.com

Investor Relations


Chau Cheng


Vice President, Investor Relations, CG Oncology


(949) 342-8939



chau.cheng@cgoncology.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.